A landmark genome-wide association study has identified 11 genomic risk loci and nine implicated genes for borderline personality disorder. Analyzing genetic data from more than one million individuals of European ancestry, the meta-analysis compared 12,339 cases with 1,041,717 controls in a discovery cohort, followed by replication across two independent datasets. Although borderline personality disorder affects roughly 0.92% to 1.90% of adults in Western populations and carries elevated rates of self-harm and suicide, no psychopharmacological therapies have received FDA approval specifically for the condition.
Researchers observed a single-nucleotide polymorphism heritability of 17.3% on the liability scale, confirming that common genetic variants contribute substantially alongside environmental factors such as early interpersonal trauma. Gene-based analyses prioritized nine genes, including FOXP1, FOXP2, SGCD, EXD3, and the X-linked gene PCYT1B. Sex-stratified analyses revealed significantly higher SNP heritability in females at 20.5% compared with 10.2% in males, though lead variants demonstrated consistent effect directions across both sexes. Enrichment testing also highlighted the sphingosine-1-phosphate receptor 3 signaling pathway as well as neuronal expression in medium spiny neurons and chandelier cells.
Derived polygenic scores explained 4.6% of phenotypic variance on the liability scale, placing individuals in the top risk decile at more than sixfold higher odds of borderline personality disorder than those in the lowest decile. Genetic correlation analyses across 50 phenotypes demonstrated extensive overlap between borderline personality disorder and post-traumatic stress disorder, major depressive disorder, attention-deficit/hyperactivity disorder, chronic pain, and suicidal behaviors. Sensitivity analyses excluding bipolar disorder and schizophrenia confirmed that these primary genetic signals were not driven solely by diagnostic overlap.
Phenome-wide association studies across two large clinical biobanks further linked polygenic liability for borderline personality disorder to multiple somatic diagnoses, including Type 2 diabetes, hypertension, obesity, gastroesophageal reflux disease, epilepsy, and chronic airway obstruction. While polygenic scores are not yet suitable for individual diagnostic screening, these findings underscore the biological vulnerability underlying borderline personality disorder and highlight the clinical need for integrated psychiatric and medical monitoring to address physical comorbidities that contribute to reduced life expectancy.
Reference
Streit F et al. Genome-wide association analyses of borderline personality disorder identify 11 loci and highlight shared risk with mental and somatic disorders. Nat Genet. 2026;58(8):1831–1844.
Microgen on adobe stock
Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.
